Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 9/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31475048 | 1.00 | ACACB (0.46) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL20195258 | 0.86 | ACACB (0.47) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL6468241 | 0.83 | ALDH1A1 (0.46) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL3939368 | 0.81 | ALDH1A1 (0.45) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL21994583 | 0.81 | ALDH1A1 (0.45) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL30583901 | 0.81 | DAO (0.49) | ACACBSCN9A | |
| SCHEMBL4541422 | 0.81 | DAO (0.49) | ACACBSCN9A | |
| SCHEMBL21503513 | 0.81 | ACACB (0.46) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL31143209 | 0.81 | ALDH1A1 (0.45) | ACACBALDH1A1ACACAPIK3CDPIK3CA | |
| SCHEMBL29796918 | 0.81 | ALDH1A1 (0.45) | ACACBALDH1A1ACACAPIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4291558-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| CN-116964048-A | Bicyclic tetrahydroazepine derivatives for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022171745-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-08-18 | — | — | WO | disclosed |
| WO-2009010784-A1 | NEW COMPOUNDS 955 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010784-A1 | NEW COMPOUNDS 955 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| CN-1960970-A | Pyrrolidine derivatives as CB1-receptor antagonists | TANABE SEIYAKU CO (JP) | 2007-05-09 | — | — | CN | disclosed |
| EP-1748980-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005115977-A1 | PYRROLIDINE DERIVATIVES AS CB1-RECEPTOR ANTAGONISTS | TANABE SEIYAKU CO., LTD. (JP) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | ACACB 3004/4885ALDH1A1 1572/4885ACACA 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.